Mitsubishi Tanabe Pharma Corporation

91 articles with Mitsubishi Tanabe Pharma Corporation

• Mitsubishi Tanabe Pharma America and NeuroDerm Announce Parkinson's Disease Presentations at American Academy of Neurology Annual Meeting

  4/18/2018

  Mitsubishi Tanabe Pharma America, Inc. and NeuroDerm Ltd. announced presentations on Parkinson's disease (PD) at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, April 21-27.

• 

  Amgen Backs Launch of Golden Ticket Winning ALS Company QurAlis

  4/5/2018

  After winning Amgen’s coveted 2017 Golden Ticket in December 2017 startup company QurAlis officially launched with financial backing from Amgen Ventures with a mission to develop a cure for Amyotrophic Lateral Sclerosis (ALS).

• Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA (edaravone) to U.S. Department of Veterans Affairs National Formulary

  11/30/2017

  The VANF criteria follow the FDA's approved labeling, and all VA requests will be determined at the national level by a single team of experts, enabling consistency across the system.

• Mitsubishi Tanabe Pharma America Expands Executive Leadership Team, Names Kevin O'Brien as Vice President of Market Access

  11/21/2017

  O'Brien will oversee the development of U.S. market access strategy and implementation, as well as payer contracting and reimbursement initiatives, to enable patient access to RADICAVA and future pipeline products.

• NeuroDerm Shareholders Approve Proposed Acquisition By Mitsubishi Tanabe

  9/12/2017

• Mitsubishi Tanabe Release: Comprehensive Edaravone Clinical Program Data Published As Supplement To Amyotrophic Lateral Sclerosis And Frontotemporal Degeneration Journal

  9/7/2017

• NeuroDerm Announces Extraordinary General Meeting Of Shareholders To Approve Acquisition By Mitsubishi Tanabe

  8/2/2017

• Mitsubishi Tanabe Coughs Up $1.1 Billion Cash for This Parkinson's Biotech

  7/25/2017

• Clinigen Signs Exclusive Supply Agreements In Global Access With Mitsubishi Tanabe, Shionogi And Romark Laboratories, L.C.

  6/21/2017

• Mitsubishi Tanabe Wins FDA Approval for Radicava, the First New ALS Drug in 22 Years

  5/8/2017

• Biogen Quietly Terminates Deal With Mitsubishi Tanabe

  1/27/2017

• Mitsubishi Tanabe Release: 12-month Edaravone Clinical Study Data In ALS Presented At The 27th International Symposium On ALS/MND

  12/9/2016

• FDA Accepts Mitsubishi Tanabe's NDA Filing For Edaravone To Treat ALS

  8/30/2016

• Mitsubishi Tanabe Joins Certara Corporation’s Simcyp Consortium

  7/20/2016

• Mitsubishi Tanabe Submits New Drug Application For Edaravone To Treat ALS In The United States

  6/20/2016

• GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck & Co., Mitsubishi Tanabe, Nipro Corporation, Sumitomo Dainippon Pharma Co., Ltd. And Salesforce.Com

  6/6/2016

• Mitsubishi Tanabe Presents Edaravone Clinical Trial Data In ALS At 2016 American Academy of Neurology Annual Meeting

  4/20/2016

• Mitsubishi Tanabe Signs Licensing Agreement With A. Menarini Asia-Pacific For Spedra (Avanafil) In 10 Countries In Asia-Pacific

  2/26/2016

• Akebia And Mitsubishi Tanabe Announce Collaboration To Develop And Commercialize Vadadustat In Asia

  12/14/2015

• Regeneron Forges $325 Million Pain Pact with Mitsubishi Tanabe

  10/5/2015